Daybreak India commoditised Novo's blockbuster obesity drug. Novo's not flinching
9 snips
Mar 31, 2026 Semaglutide goes generic in India, triggering a predicted 85-90% price plunge and reshaping competitive dynamics. Discussion covers how Eli Lilly overtook market share with aggressive pricing and stronger results. Novo's strategy pivots from drug defense to buying hospitals, data and care platforms. The episode examines partnerships, single‑specialty bets, and efforts to stay present across the patient journey.
AI Snips
Chapters
Transcript
Episode notes
First-Mover Loss And Patent Cliff In India
- Novo Nordisk lost first-mover advantage in India after Eli Lilly's Mounjaro launched three months earlier and outsold Wegovy 10 to 1.
- Semaglutide's patent expiry in India means generics will cut prices by 85–90%, reshaping the market dynamics.
How Mounjaro Outran Wegovy In India
- Eli Lilly's Mounjaro launched three months before Wegovy in India and became the fastest drug to cross 1 crore rupees in cumulative sales.
- Within six months Mounjaro outsold Wegovy by 10 to 1, forcing Novo to cut prices 37% early on.
Dual Strategy Of Premium Brand And Volume Partnerships
- Novo responded by selling lower-cost versions via partners (Povistra with M-Cure, Extensio with Abbott) and by partnering with Healthify Me for integrated care.
- This preserves premium branding while letting Novo participate in high-volume, lower-price segments.